201911 - Tripodi - Immunoterapia specifica alla luce della e-mobile health?Asmallergie
1. The document discusses using digital solutions like mobile health to improve allergen immunotherapy (AIT) by combining clinical research data and mobile health for AIT prescription.
2. It proposes the "@IT-2020" process, a flexible 4-step modular approach for prescribing AIT for pollen allergy patients in Southern Europe/Mediterranean countries, to be validated in a pilot study (2016-2017) and multicenter study (2018-2019).
3. The 4 diagnostic steps of "@IT-2020" and validation testing are described, aiming to determine genuine vs false sensitization, primary sensitization, and the relationship between sensitization and symptoms to guide personalized AIT prescription.
201911 - Tripodi - Immunoterapia specifica alla luce della e-mobile health?Asmallergie
1. The document discusses using digital solutions like mobile health to improve allergen immunotherapy (AIT) by combining clinical research data and mobile health for AIT prescription.
2. It proposes the "@IT-2020" process, a flexible 4-step modular approach for prescribing AIT for pollen allergy patients in Southern Europe/Mediterranean countries, to be validated in a pilot study (2016-2017) and multicenter study (2018-2019).
3. The 4 diagnostic steps of "@IT-2020" and validation testing are described, aiming to determine genuine vs false sensitization, primary sensitization, and the relationship between sensitization and symptoms to guide personalized AIT prescription.
201911 - Rossi - L'asma grave è sempre “grave”?Asmallergie
This document discusses a study of 437 patients with severe asthma (GINA step V) in Italy. The main findings were:
- The average annual exacerbation rate was 3.75.
- The mean blood eosinophil level was 536.7 cells/mcL and average serum total IgE was 470.3 kU/L.
- 64% were on regular oral corticosteroids, 57% with omalizumab and 11.2% with mepolizumab.
- The most common comorbidities were rhinitis, nasal polyposis, and bronchiectasis. Bronchiectasis was associated with more frequent severe exacerbations.
201911 - Conte - Asma eosinofilico: i farmaci biologici che contrastano l'azi...Asmallergie
This document summarizes a presentation about eosinophilic asthma and biological drugs that target interleukin-5 (IL-5). It discusses the role of eosinophils and IL-5 in asthma, clinical studies of anti-IL-5 drugs like mepolizumab and benralizumab, and real-world experience with these therapies. The presentation covers the pathophysiology of eosinophilic asthma, how anti-IL-5 drugs work, results from major clinical trials showing reduced exacerbations and oral corticosteroid use, and insights from real-world studies on treatment response and outcomes. It emphasizes the importance of patient phenotypes and endotypes in guiding therapy selection for severe asthma.
201911 - Villalta - Novità in ambito di diagnostica molecolare nella sensibil...Asmallergie
This document discusses advances in molecular diagnostics for mite sensitization. It begins with a brief history of allergy to house dust mites and an overview of the major allergenic molecules from mites, including Der p 1, Der p 2, and Der p 23. It describes the concept of "molecular spreading" where the IgE response spreads from initial sensitization to major allergens to include other milder allergens over time. The document then covers classical and molecular diagnostic techniques for mite allergy. It concludes by discussing the potential predictive role of antibody patterns to different mite allergens.
20181110 - Polla - Nuove associazioni inalatorie nella terapia dell’asma bron...Asmallergie
This document discusses new inhaler combinations for treating asthma. It summarizes several clinical studies that evaluated the efficacy of combining inhaled corticosteroids and long-acting muscarinic antagonists to control asthma symptoms. One study of over 5,000 patients found that combining these drugs reduced the risk of exacerbations compared to inhaled corticosteroids alone. The document also references guidelines from GINA that recommend stepwise treatment with inhaled corticosteroids and adding long-acting beta-agonists or tiotropium for uncontrolled asthma.
201911 - Rossi - L'asma grave è sempre “grave”?Asmallergie
This document discusses a study of 437 patients with severe asthma (GINA step V) in Italy. The main findings were:
- The average annual exacerbation rate was 3.75.
- The mean blood eosinophil level was 536.7 cells/mcL and average serum total IgE was 470.3 kU/L.
- 64% were on regular oral corticosteroids, 57% with omalizumab and 11.2% with mepolizumab.
- The most common comorbidities were rhinitis, nasal polyposis, and bronchiectasis. Bronchiectasis was associated with more frequent severe exacerbations.
201911 - Conte - Asma eosinofilico: i farmaci biologici che contrastano l'azi...Asmallergie
This document summarizes a presentation about eosinophilic asthma and biological drugs that target interleukin-5 (IL-5). It discusses the role of eosinophils and IL-5 in asthma, clinical studies of anti-IL-5 drugs like mepolizumab and benralizumab, and real-world experience with these therapies. The presentation covers the pathophysiology of eosinophilic asthma, how anti-IL-5 drugs work, results from major clinical trials showing reduced exacerbations and oral corticosteroid use, and insights from real-world studies on treatment response and outcomes. It emphasizes the importance of patient phenotypes and endotypes in guiding therapy selection for severe asthma.
201911 - Villalta - Novità in ambito di diagnostica molecolare nella sensibil...Asmallergie
This document discusses advances in molecular diagnostics for mite sensitization. It begins with a brief history of allergy to house dust mites and an overview of the major allergenic molecules from mites, including Der p 1, Der p 2, and Der p 23. It describes the concept of "molecular spreading" where the IgE response spreads from initial sensitization to major allergens to include other milder allergens over time. The document then covers classical and molecular diagnostic techniques for mite allergy. It concludes by discussing the potential predictive role of antibody patterns to different mite allergens.
20181110 - Polla - Nuove associazioni inalatorie nella terapia dell’asma bron...Asmallergie
This document discusses new inhaler combinations for treating asthma. It summarizes several clinical studies that evaluated the efficacy of combining inhaled corticosteroids and long-acting muscarinic antagonists to control asthma symptoms. One study of over 5,000 patients found that combining these drugs reduced the risk of exacerbations compared to inhaled corticosteroids alone. The document also references guidelines from GINA that recommend stepwise treatment with inhaled corticosteroids and adding long-acting beta-agonists or tiotropium for uncontrolled asthma.
20181110 - Polla - Nuove associazioni inalatorie nella terapia dell’asma bron...
20171111 - Beatrice - I farmaci che possono gestire la patologia turbinale
1. I FARMACI CHE POSSONO GESTIRE
LA PATOLOGIA TURBINALE
Fabio Beatrice
2. L’ostruzione nasale cronica è uno
dei sintomi di più comune riscontro
in ambito otorinolaringoiatrico
L’ipertrofia del turbinato inferiore è una causa
molto frequente di ostruzione respiratoria
nasale
(Otolaryngo Pol 2016; 70 (4): 22-27)
Colpisce circa il 20% dei cittadini europei
(Otolaryngol. Head Neck Surg 137:256–63,2007)
3. “The common causes of inferior turbinate hypertrophy are
vasomotor rhinitis, nasal septal deviation, allergic rhinitis,
and chronic sinusitis”
Both medical and surgical treatments are used for the
treatment of inferior turbinate hypertrophy. Medical
treatment includes topical and systemic antihistamines,
decongestants, and topical steroids. When medical therapy
fails, surgical treatment can be applied
Both medical and surgical treatments are used for the
treatment of inferior turbinate hypertrophy.
Medical treatment includes topical and systemic
antihistamines, decongestants, and topical steroids. When
medical therapy fails, surgical treatment can be applied.
(Otolaryngo Pol 2016; 70 (4): 22-27)
4. Il target è il turbinato inferiore
Turbinato inferiore sinistro
9. FARMACI PER CONTROLLARE
L’IPERTROFIA DEI TURBINATI
INFERIORI NELLE VARIE FORME DI
RINITE
Steroidi topici
Antistaminici in via topica e sistemica
Decongestionanti
10. ESISTE UN RUOLO CENTRALE PER LO
STEROIDE AD USO NASALE TOPICO
NELLA PATOLOGIA TURBINALE
Beclometasone
Preferibile uso sopra i 6 anni di età
Uno degli schemi più utilizzati è 2 puff per narice per 2 volte
al giorno per 30 giorni.
Importanza di un impiego regolare e per più giorni .
Verificare coesistenza di comorbilità per evitare effetti
collaterali
11. LA QUESTIONE DELLA COESISTENZA
DELLA IPERTROFIA TURBINALE CON
ALTRE PATOLOGIE NASO SINUSALI
18. FARMACI DA UTILIZZARE NEL
CONTROLLO DELLA SINUSITE
ETMOIDO MASCELLARE E DOPO
INTERVENTO DI FESS CORREDATO
DA TURBINOPLASTICA
19. QUESITI
Dopo l’intervento come usate i seguenti prodotti
Creme/pomate nasali riepitelizzanti?
Lavaggetti nasali ? Isotonici o ipertonici?
Antibiotici ?
Come usate i cortisonici topici?
Come usate gli antistaminici topici ?
Altro?